CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scott_jiminez who wrote (597)	7/11/2000 9:18:05 AM
From: nigel bates	Read Replies (2) of 675

Is this still going ahead, and if so, does anyone know the CeNeS base price for the transaction (I emailed CeNeS IR, and will post any reply) ? (Looking at buying some CeNeS...) - "The proposed merger, which is subject to shareholder approval by both companies, is structured as an all stock transaction. Cambridge NeuroScience shareholders will receive CeNeS shares equal to a value of $2.25 for each CNSI share. If the price of CeNeS stock increases up to 12.5% between now and the closing, Cambridge NeuroScience shareholders will receive an amount of CeNeS shares equal to $2.25 per share while an increase of greater that 12.5% results in a fixed amount of shares. If the price of CeNeS stock decreases as much as 22.5%, Cambridge NeuroScience shareholders will receive additional shares to maintain the value of the transaction. The tax free transaction will be treated by CeNeS pursuant to the purchase method of accounting. The transaction is expected to be completed in the third quarter 2000 and CeNeS will continue to trade on the London Stock Exchange after the closing of the transaction."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next